Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$156 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-7.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2
Industry P/E
24.51
EV/EBITDA
-0.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-5.9
Face value
--
Shares outstanding
911,330,225
CFO
$-544.50 Mln
EBITDA
$-559.34 Mln
Net Profit
$-586.87 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kala Pharmaceuticals (KALA)
| -69.4 | -55.2 | -69.4 | -97.0 | -77.6 | -78.3 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Kala Pharmaceuticals (KALA)
| -92.0 | -0.9 | -81.7 | 26.1 | -82.2 | 83.7 | -24.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kala Pharmaceuticals (KALA)
|
0.2 | 155.8 | 0.3 | -35.8 | -12,328.3 | -- | -- | 2.0 |
| 12.5 | 3,812.0 | 3,018.8 | 72.1 | 12.6 | -80 | 54.3 | 86.1 | |
| 168.5 | 8,210.1 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.9 | |
| 73.2 | 13,446.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 42.5 | 4,055.0 | 761.4 | 99.7 | 7.3 | 15 | 46.5 | 5.7 | |
| 13.3 | 11,237.7 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 18.7 | 2.9 | |
| 23.1 | 11,653.6 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.2 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 199.6 | 3,841.5 | 268.1 | 124.5 | 60.0 | 13.5 | 31.5 | 4.0 | |
| 37.7 | 3,099.9 | 158.3 | -68.9 | -29.3 | -113 | -- | 69.3 |
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical... trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts. Address: 1167 Massachusetts Avenue, Arlington, MA, United States, 02476 Read more
Chairman & CEO
Mr. Mark T. Iwicki
Chairman & CEO
Mr. Mark T. Iwicki
Headquarters
Arlington, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Kala Pharmaceuticals Inc (KALA) is $0.17 (NASDAQ) as of 02-Apr-2026 19:54 EDT. Kala Pharmaceuticals Inc (KALA) has given a return of -77.55% in the last 3 years.
Since, TTM earnings of Kala Pharmaceuticals Inc (KALA) is negative, P/E ratio is not available.
The P/B ratio of Kala Pharmaceuticals Inc (KALA) is 1.98 times as on 31-Mar-2026, a 65 discount to its peers’ median range of 5.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-0.85
|
2.64
|
|
2023
|
-0.45
|
2.53
|
|
2022
|
-1.37
|
3.24
|
|
2021
|
-0.01
|
0.09
|
|
2020
|
-0.07
|
0.08
|
The 52-week high and low of Kala Pharmaceuticals Inc (KALA) are Rs 20.60 and Rs 0.15 as of 04-Apr-2026.
Kala Pharmaceuticals Inc (KALA) has a market capitalisation of $ 156 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Kala Pharmaceuticals Inc (KALA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.01
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.